Finvest
ILMN Healthcare · Genomics · Life science tools · Sequencing · Thesis updated June 12, 2026

Clinical demand is carrying Illumina

01 Running thesis

One engine is doing the work

Illumina is improving, but the recovery is not balanced. Q1 2026 revenue rose 5% to $1.091 billion, and management raised full-year guidance. The clear bright spot is clinical sequencing, where consumables grew 20% ex-China for the second quarter in a row.

The bull case is simple: more NovaSeq X machines in the field today can mean more high-margin consumables later. Illumina placed over 80 NovaSeq X systems in Q1, about 20 more than Q1 2025. Clinical customers also made up more than 65% of sequencing consumables revenue in the quarter.

The bear case is that clinical is carrying too much of the load. Research consumables ex-China fell 12%, and management still expects the research and applied group to decline for the full year. If clinical growth slows before research recovers, growth could look thin fast.

Finn's view is mixed but leaning constructive. Illumina has a strong balance sheet and a large installed base, but sentiment is weak because investors still need proof that research demand can bottom and that new competition will not force lower prices.

May 2026→The Q1 2026 10-Q confirmed the main story: revenue rose 5% to $1.091 billion, clinical sequencing helped growth, and Greater China stayed a headwind.
Apr 2026▲Q1 earnings beat expectations and guidance moved higher. Clinical consumables grew 20% ex-China again, and NovaSeq X placements topped 80.
Feb 2026→The 2025 10-K showed Core Illumina revenue of $4.34 billion, about flat with 2024. It also confirmed tariff costs, China risk, and the completed SomaLogic acquisition.
Feb 2026▲Q4 2025 results showed 5% revenue growth and strong clinical consumables demand ex-China. The SomaLogic deal moved from plan to execution.
Oct 2025→The Q3 2025 10-Q confirmed that NovaSeq X consumables were helping, while research budgets and China pressure still limited total growth.
Oct 2025▲Q3 2025 earnings showed the NovaSeq X transition moving faster than planned. Clinical demand kept improving, while research looked more stable but not strong.
Aug 2025→Q2 2025 showed the same two-speed market: clinical consumables were resilient, while research instrument demand stayed weak. The SomaLogic deal added a longer-term protein data option.
02 Business model

Machines first, refills for years

Illumina sells DNA sequencers and array systems, then sells the consumables those systems need to run. Consumables include reagents, flow cells, and sample prep kits. This is a razor-and-blade model, where the machine opens the door and repeat use drives much of the profit.

The best part of the model is the installed base. Once a lab builds its workflow around an Illumina system, switching takes time, money, staff training, and data validation. That gives Illumina pricing power, though not unlimited power.

The model breaks if customers stop buying new instruments, run fewer samples, or move to rival platforms. Research labs are already delaying spending because of budget pressure and NIH funding worries. Clinical labs are filling the gap for now.

03 Product portfolio

From DNA reads to protein data

Growth engine

NovaSeq X

This is Illumina's high-throughput sequencing platform. Over 80 systems were placed in Q1 2026, and growth in its installed base should feed future consumables demand.

Cash cow

Sequencing consumables

These are reagents, flow cells, and kits used each time a sequencer runs. They produced $797 million of Q1 2026 revenue and are the heart of the repeat sales model.

Steady

Desktop and mid-throughput sequencers

These systems serve labs that do not need the scale of NovaSeq X. Demand can be tied to research budgets, which remain under pressure.

Steady

Array products

Arrays help test known genetic markers at scale. They are useful in genotyping and applied markets, but they are not the main growth story today.

Option

SomaLogic proteomics

Illumina acquired SomaLogic on January 30, 2026 to add protein measurement to its tools. This supports multi-omics, which means studying DNA, RNA, proteins, and other biology together.

Steady

Services and other revenue

This includes service contracts, support, and SomaLogic-related services. Q1 2026 service and other revenue was $174 million, up from $161 million a year earlier.

04 Business segments

Q1 revenue mix

Consumables73%modest
Instruments11%modest
Service and other revenue16%modest

The mix below uses Illumina's Q1 2026 product revenue disclosure, not end-market demand. Consumables dominate, while clinical demand is the key driver inside sequencing consumables.

05 Risk factors

What could go wrong

Clinical growth slows

High impact · Medium odds

Clinical sequencing is doing most of the growth work. In Q1, clinical consumables grew 20% ex-China and made up more than 65% of sequencing consumables revenue. If that growth rate cools before research recovers, the company could miss its growth plan.

We watchClinical sequencing consumables growth ex-China, especially whether it stays near 20%.

Research demand keeps falling

High impact · High odds

Research remains the weak side of the business. Ex-China research consumables fell 12% in Q1, and management's full-year view still points to a decline in research and applied markets. Weak grants, hiring delays, and lab budget limits can keep instrument and consumable demand low.

We watchResearch and applied consumables growth, NIH funding signals, and customer comments on project delays.

China stays uncertain

Medium impact · High odds

Greater China revenue fell by $20 million in Q1 2026 because Illumina is on China's List of Unreliable Entities. Instrument exports are now allowed on a case-by-case approval basis, but that is still not a normal sales setup. A tougher ruling or slow approvals could keep the region under pressure.

We watchGreater China revenue, export approvals, and any change to Illumina's status on the List of Unreliable Entities.

Competitors pressure price

Medium impact · Medium odds

New competitive launches are expected around summer 2026. Management has played down the threat, but lower-cost systems or flow cells could test Illumina's pricing. This matters most if customers delay purchases to compare platforms.

We watchManagement commentary on summer 2026 launches, NovaSeq X placements, and any change in consumables pricing.

Tariffs and costs squeeze margins

Medium impact · Medium odds

Q1 gross margin was 66.1%, up slightly from 65.6% a year earlier, but tariffs and lower-margin SomaLogic revenue held it back. Illumina says tariff costs remain a headwind and refund timing is uncertain. Higher fuel, energy, memory chip, or freight costs could also weigh on profit.

We watchGross margin, tariff recoveries, and management updates on supply chain cost mitigation.
06 Quick answers

In one breath

How does Illumina make money?

Illumina sells sequencing and array instruments, then sells the consumables and services needed to use them. In Q1 2026, consumables were $797 million of its $1.091 billion in revenue.

Why is NovaSeq X important?

NovaSeq X is Illumina's high-throughput sequencing platform. More placements expand the installed base, which can drive years of future consumables use.

Is Illumina still exposed to GRAIL?

GRAIL, which sells the Galleri multi-cancer early detection test, is no longer part of Illumina's core business after the spin-off. Illumina still reports some remaining financial items tied to GRAIL, but the operating story is now centered on sequencing and SomaLogic.

What is the biggest debate on ILMN stock?

The debate is whether clinical growth can more than offset weak research demand and China pressure. Investors also need to see how new competitors affect NovaSeq X demand and pricing.